Magazine reported MSA American Medical Association in its monthly report for more drugs lethal to humans as indicated in its official report that the highest mortality rate in the world are using the treatment of AVANDIA as the number of deaths in one year 1354 patients solving treatment EXJADE second in the annual number of deaths in the world at 1320 patients as the risk to the kidneys, liver, large, and the magazine based its report on the statistics issued by the Drug Administration FDA.
For his part, said pharmaceutical Abdullah al that the treatment of AVANDIA has been turned off recorded in Saudi Arabia by the Food and Drug Authority as a result of significant risks to the patient and sent doctors need to use safe alternatives, and with respect EXJADE reported that he is still in the Saudi market and the FDA issued a warning for patients and doctors need to apply precautionary things for the patient and follow-up to the kidneys and liver regularly. Did not stop recording until now.
He added that all drugs that have been a warning to her safe alternatives should be described to the patient rather than drugs that have been warning about.
He pointed out that EXJADE used as a treatment for patients with thalassemia, where the genetic blood diseases, most notably sickle cell anemia and thalassemia, and HIV yeast G6PD spread in the eastern region, where is the Qatif provinces with the highest incidence of these diseases, particularly sickle cell disease. The prevalence rates characteristic sickle-cell anemia in the eastern 30 percent of the thalassemia are the proportions of carriers designated 20 percent, according to statistics, stressing that the sickle-cell anemia is spread widely in the Kingdom and the rates by between 1.75 percent and 2.35 percent, and the proportion of pregnancy attribute between 20 and 30 percent .
She explained that the prevalence of the disease in Qatif high compared to other regions, because the rate of pregnancy attribute to 30 percent.
The General Authority for Food and Drug demanded earlier to take precautionary measures to reduce the risks concerning the use of medication Deferasirox, and marketed in the Kingdom of the brand name Exjade on the following risks related to renal failure acute, high level of creatinine, diseases of the urinary tract, and the high level of liver enzymes, bleeding in the digestive system .
The authority said in a statement posted on its website that the product is used to treat cases increase the rate of iron in the blood, which may result from blood transfusions frequently (more than 7 ml / kg / month) for patients who suffer from Thalassemia age of 6 years and over ... Also used as an alternative to drug deferoxamine in the event of impediments to the use or non-responsive patients with lotion deferoxamine, for the treatment of increasing the rate of iron in the blood, which may result from the following diseases: anemia other patients have two to five years, and the high level of iron in the blood of patients with thalassemia, which result from the non-recurrent blood transfusion (less than 7 ml / kg / month) .. Need to take precautionary measures.
The contingency plans to reduce the risks concerning the use of Exjade on the kidneys and digestive tract and the liver.
It invited the Food and Drug healthcare professionals to inform the National Center for pharmacovigilance in case of any side effects from the use of deferasirox Deferasirox product marketed under the brand name Exjade .